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T ea is the most widely consumed beverage in the world.  Green tea contains a variety of polyphe-
nols known as catechins.  Major components of tea 
polyphenols are epicatechin,  epigallocatechin,  epicat-
echingallate and (−)-epigallocatechin-3-gallate (EGCG) 
(Fig. 1) [1 , 2].  EGCG is the most abundant and biolog-
ically active compound in green tea [3].  It has been 
shown to inhibit enzyme activities and some signal 
transduction pathways,  resulting in the suppression of 
cell proliferation and enhancement of apoptosis,  as well 
as the inhibition of cell invasion,  angiogenesis and 
metastases [4 , 5].
Lung cancer is the most common cause of cancer 
death in many countries.  Oncogene drivers—including 
epidermal growth factor receptor (EGFR) mutation and 
fusion gene rearrangement between echinoderm micro-
tubule-associated protein-like 4 (EML4) and anaplastic 
lymphoma kinases (ALK)—play important roles in the 
carcinogenesis and tumor progression of non-small cell 
lung cancer (NSCLC).  These EGFR mutations and 
fusion gene rearrangements can be suppressed by EGFR 
tyrosine kinase inhibitors (TKIs) such as gefitinib and 
erlotinib [6] and ALK TKIs such as crizotinib [7],  
respectively.  Recently,  c-ros oncogene 1 (ROS1) fusion 
genes whose partners were SLC34A2,  CD74 or FIG 
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(−)-Epigallocatechin-3-gallate (EGCG) has been shown to bind to several receptors including epidermal growth 
factor receptor (EGFR).  EGFR tyrosine kinase inhibitors and anaplastic lymphoma kinase (ALK) inhibitors are 
effective for non-small cell lung cancers harboring activating EGFR mutations and ALK or c-ros oncogene 1 
(ROS1) fusion genes,  respectively.  We investigated the effects of EGCG on EGFR- or fusion gene-driven lung 
cancer cells such as PC-9,  RPC-9,  H1975,  H2228 and HCC78.  The five cell lines had similar sensitivity to 
EGCG.  Phosphorylated (p)EGFR,  pAkt and pErk in PC-9,  RPC-9 and H1975 cells were suppressed by EGCG 
(50 or 100 μM).  EGCG also inhibited pALK in H2228,  pROS1 in HCC78,  and pErk and pAkt in both cell lines.  
All the xenograft tumors established using the 5 cell lines in EGCG-treated groups were significantly smaller 
than the tumors in the vehicle-treated groups.  The numbers of tumor blood vessels of xenograft tissues in 
EGCG-treated mice were significantly lower than those in vehicle-treated mice.  In conclusion,  EGCG may be 
effective for EGFR-driven lung tumors irrespective of the presence of T790M,  and for ALK or ROS1 fusion 
gene-driven lung tumors.
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were discovered to be oncogene drivers,  and crizotinib 
found to be effective for these lung cancers as well [8 , 9].  
In this study,  we attempted to clarify whether EGCG 
has an inhibitory effect against EGFR-,  ALK- or ROS1-
driven lung tumors.
Materials and Methods
Reagents and antibodies. EGCG (> 95% purity;  
Sigma-Aldrich,  Tokyo,  Japan) was prepared as a 10 mM 
stock solution,  and diluted into culture media immedi-
ately prior to the experiments.  Rabbit antisera against 
EGFR,  phospho-specific (p) EGFR (pY1068),  Erk,  
pErk,  Akt,  pAkt (pSer473),  ALK,  pALK,  ROS1,  
pROS1 and GAPDH were purchased from Cell 
Signaling Technology (Tokyo,  Japan).  Antibody against 
hypoxia-induced factor 1α (HIF)-1α was purchased 
from BD Biosciences (Tokyo,  Japan).  Antibody against 
CD31 (platelet endothelial cell adhesion molecule) used 
in the immunohistochemical analyses was also pur-
chased from Cell Signaling Technology.
Cell lines and culture. The NSCLC cell lines PC-9 
and H1975 were purchased from Immuno-Biological 
Laboratories (Takasaki,  Japan).  H2228 and HCC78 
were obtained from the American Type Culture 
Collection (Manassas,  VA,  USA).  The cells were cul-
tured in RPMI 1640 containing 10% fetal bovine serum 
(FBS; complete medium).  All cells were maintained 
under a 5% CO2-humidified atmosphere at 37°C.  Cells 
were subcultured once and reached 80-90% confluency.  
RPC-9 cells with an EGFR T790M mutation were estab-
lished from parental PC-9 cells harboring an EGFR 
exon 19 deletion mutation in our laboratory [10].  
RPC-9 cells showed a 400-fold resistance to gefitinib 
compared with parental PC-9 cells.  H1975 cells carried 
an EGFR exon 21 missense mutation (L858R) and exon 
20 T790M mutation [6].  H2228 cells and HCC78 cells 
harbored the EML4-ALK fusion gene and SLC34A2-
ROS1 fusion gene,  respectively [7 , 8].
Cell growth assay. Cells were plated in 96-well 
plates at 3,000 cells per well in complete medium and 
then were incubated with different concentrations of 
EGCG for 96 h.  Cell viability was assessed using a 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay [11].  The percentage of surviving 
cells was calculated using the following formula:  
[(mean fluorescence in 6 test wells - fluorescence in 
background wells) / (mean fluorescence in control wells 
- fluorescence in background wells)] × 100.  The drug 
concentration required to inhibit the growth of tumor 
cells by 50% (IC50) for 96 h exposure was determined by 
plotting the logarithm of drug concentration versus the 
percentage of surviving cells.  Determinations were car-
ried out in quadruplicate in each experiment and results 
were confirmed in 3 or more separate experiments.
Western blotting. After treating with EGCG (50 
or 100 μM) for 20 h,  cells were immediately harvested 
and disrupted.  Cells were lysed in radioimmunopre-
cipitation assay buffer [1% Triton X-100,  0.1% SDS,  
50 mmol/L Tris-HCl (pH 7.4),  150 mmol/L NaCl,  
1 mmol/L EDTA,  1 mmol/L EGTA,  10 mmol/L β- 
glycerol phosphate,  10 mmol/L NaF,  and 1 mmol/L 
sodium orthovanadate-containing protease inhibitor 
tablets (Roche Applied Sciences GmbH,  Mannheim,  
Germany)].  Proteins were separated by electrophoresis 
on polyacrylamide gels,  transferred onto nitrocellulose 
membranes,  and probed with specific antibodies fol-
lowed by detection with Enhanced Chemiluminescence 
Plus (GE Healthcare Biosciences,  Tokyo,  Japan).  Protein 
expression was assessed by densitometry using ImageJ 
software (developed at the National Institutes of Health).
Xenograft model. Female BALB/C nu/nu mice 
(6-week-old; Japan Charles River Co.,  Kanagawa,  
Japan) were injected with 2 × 106 PC-9,  RPC9,  H1975,  
H2228 or HCC78 cells in 100 μl phosphate buffered 
saline and 100 μl matrigel subcutaneously into the 
upper flank region.  The mice were orally treated with 
0.5% (w/v) EGCG or water in a water bottle for 6 weeks 
(PC-9,  RPC-9 and H1975) or 8 weeks (H2228 and 
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Fig. 1　 Structure of the green tea polyphenols.
HCC78) after injection of cancer cells.  Tumors became 
measurable by day 10 post-implantation and were mea-
sured with digital calipers twice a week.  Tumor vol-
umes were calculated by the equation: volume=  
length × width2 × 0.5.  The mice were sacrificed at of day 
42 (PC-9,  RPC-9 and H1975) or day 56 (H2228 and 
HCC78) post-implantation and the tumors were surgi-
cally removed.
Immunohistochemistry. Deparaffinized sections 
were unmasked in antigen-unmasking solution (DAKO,  
Copenhagen,  Denmark) in a microwave oven for anti-
gen retrieval.  Endogenous peroxidase was quenched 
using 3% H2O2,  and then the sections were blocked for 
1 h at room temperature and incubated with CD31 anti-
body (1 : 20) overnight at 4°C.  Biotin-conjugated sec-
ondary antibody (1 : 200) and avidin−biotin peroxidase 
complex (1 : 100) were then applied.  Finally,  the sec-
tions were counterstained with hematoxylin.  CD31-
positive blood vessels were counted in ten random fields 
( × 200).
Statistical analysis. All data were presented as the 
mean ± standard deviation (SD).  Student’s t-test was 
used to test differences between 2 groups.  Values of 
p < 0.05 were considered to indicate statistical signifi-
cance in the two-tailed comparison.  All data were ana-
lyzed using Microsoft Office Excel 2010 (Microsoft 
Japan Corporation,  Tokyo,  Japan).
Results
Effect of EGCG in vitro. EGCG was found to have 
effects on all 5 cell lines (PC-9,  RPC-9,  H1975,  H2228 
and HCC78) in a dose-dependent manner.  The IC50 
values ranged between 22 μM and 57 μM (Table 1).  
Next,  we examined the effects of EGCG on the phos-
phorylation of EGFR,  ALK and ROS1 in the cells 
(Fig. 2A).  pEGFR was inhibited by a 20-h pretreatment 
with 50 or 100 μM EGCG in PC-9,  RPC-9 and H1975 
cells.  EGCG also suppressed pAkt and pErk,  down-
stream signals of EGFR,  in the same 3 cell lines.  In 
H2228 cells,  pALK,  pAkt and pErk were also inhibited.  
In the HCC78 cells,  pEGFR,  pAkt,  pErk and pROS1 
were suppressed.  The ratios of pEGFR to total (t) EGFR 
in PC-9,  RPC-9 and H1975 cells,  of pALK to tALK in 
H2228 cells,  and of pROS1 to tROS1 in HCC78 cells 
were significantly reduced by EGCG treatment (Fig. 2B).
Effect of EGCG in vivo. EGCG or vehicle treat-
ments of the tumor xenografts from each of the five cell 
lines are shown in Fig. 3.  On day 42 after xenograft,  the 
sizes (mm3; mean ± SD) of the tumors derived from 
PC-9 cells were 1,114 ± 478 (n = 10) in the EGCG group 
and 2,803 ± 973 (n = 9) in the control group (p < 0.05).  
Similarly,  the xenograft tumors derived from RPC-9 
cells in the EGCG group on day 42 were significantly 
smaller (371± 262,  n= 13) than those (760± 352,  n= 11) 
in the control group (p < 0.05).  H1975 xenografts in the 
EGCG group on day 42 were significantly smaller 
(1,579 ± 1,104,  n = 9) than those (3,435 ± 1,719,  n = 7) in 
the control group (p < 0.05).  On day 56 after xenograft,  
the tumors derived from H2228 cells in the EGCG 
group were significantly smaller (170 ± 128,  n = 9) than 
those (260 ± 240,  n = 9) in the control group (p < 0.05).  
The HCC78 tumors on day 56 after xenograft were also 
significantly smaller in the EGCG group (51±10,  n=12) 
than in the control group (116 ± 29,  n = 6) (p < 0.05).  
There were no significant differences in body weight 
between the EGCG group and control group (Fig. 4).
In order to evaluate the antiangiogenic properties of 
EGCG,  we utilized immunostaining.  CD31-positive 
blood vessels in the tumors treated by EGCG or vehicle 
are shown in Fig. 5A.  In all xenograft models,  the 
tumors treated with EGCG exhibited significantly fewer 
tumor vessels (all p < 0.05; Fig. 5B).  To examine the 
cause of the suppressive effect of EGCG on neovascu-
larization,  we measured the HIF-1α levels in the cells.  
The results showed that the levels of HIF-1α in PC-9,  
RPC-9,  H1975,  H2228 and HCC78 cells were all 
inhibited by 100 μM of EGCG (Fig. 6).
Discussion
EGCG was previously shown to inhibit both EGFR 
mutant and wild type lung cancer cells [12 , 13].  In the 
present study,  we revealed that EGCG inhibited cell 
growth irrespective of EGFR-,  ALK- or ROS1-
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Table 1　 Sensitivity to EGCG
Cell line IC50 (µM)
PC-9 43.33±7.03
RPC-9 37.48±3.64
H1975 32.47±0.61
H2228 57.46±7.64
HCC78 22.42±0.92
EGCG,  (-)-epigallocatechin-3-gallate; IC50,  inhibitory concentration 
of cell growth by 50%.
dependency.  In addition,  we showed that EGFR TKI-
resistant cells harboring a T790M mutation were sup-
pressed by EGCG.  Finally,  we revealed that lung cancer 
cells driven by EML4-ALK or SLC34A2-ROS1 fusion 
genes were also inhibited by EGCG.
EGFR-activating mutations in NSCLC represent an 
example of oncogene addiction [4],  and tumors har-
boring the mutations are quite sensitive to gefitinib and 
erlotinib.  But even in cancers with the activating muta-
tions,  resistance to EGFR TKIs frequently develops 
after several months of the treatment.  Approximately 
half of the resistant tumors would have a secondary 
T790M mutation.
Although osimertinib was recently approved and 
shown to have great efficacy in patients with T790M-
positive advanced NSCLC [14],  no other drugs have 
been proven effective and made clinically available for 
these resistant tumors.  Therefore,  T790M-positive 
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Fig. 2　 (A) Eﬀects of EGCG on EGFR,  ALK,  ROS1 and its downstream signaling in PC-9,  RPC-9,  H1975,  H2228 and HCC78 cells.  
Cells were incubated with EGCG 50 µM or 100 µM for 20 h and cell lysates were subjected to immunoblot analysis with the antibodies.  
E(50): EGCG 50 µM; E(100): EGCG 100 µM.  (B) Protein expression was assessed by densitometry using ImageJ software (developed at 
the National Institutes of Health). The ratios of pEGFR to total (t)EGFR in PC-9,  RPC-9 and H1975 cells,  of pALK to tALK in H2228 cells,  
and of pROS1 to tROS1 in HCC78 cells were signiﬁcantly reduced by EGCG treatment.  Studentʼs t-test.  ＊＊p＜0.01.
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Fig. 3　 Growth curves of PC-9,  RPC-9,  H1975,  H2228 and HCC78 xenograft tumors in mice receiving 0.5% (w/v) EGCG (broken line) 
or water (solid line).  Mean tumor volumes of 6-13 tumors per group are shown.  Diﬀerences in the tumor volume at day 42 (PC-9,  RPC-9 
and H1975) or day 56 (H2228 and HCC78) were compared using Studentʼs t-test.  ＊p＜0.05.
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Fig. 4　 Changes in the body weights of PC-9,  RPC-9,  H1975,  H2228 and HCC78 xenograft mice.  Body weight was measured twice a 
week.  There were no signiﬁcant diﬀerences of body weights between the EGCG group (broken line) and control group (solid line).
advanced NSCLC patients who cannot use osimertinib 
may be good candidates for EGCG therapy.  The 
NSCLC tumors harboring ALK or ROS1 fusion genes 
would also be resistant to crizotinib after approximately 
1 to 1.5 years of treatment [7 , 15 , 16].  The response rate 
of ceritinib,  another recently approved ALK inhibitor,  
was previously reported as 58% among 80 ALK-positive 
patients who had been treated with crizotinib [17].  
Despite these promising results with ceritinib,  however,  
EGCG may be effective in cases of fusion gene-driven 
lung tumors refractory to crizotinib.  Unfortunately,  
since we did not have crizotinib-resistant H2228 or 
HCC78 cells,  we could not examine this issue in the 
present work.
Angiogenesis,  the process of blood-vessel growth,  is 
a critical event during development,  as well as during 
tumor invasion and metastasis [18].  We showed that all 
the xenograft tumors derived from the 5 cell lines used 
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Fig. 5　 (A) Tumor angiogenesis assessed by CD31 immunohistochemical staining.  The mice were treated with EGCG or water.  The 
xenograft tumor specimens grown from PC-9,  RPC-9,  H1975,  H2228 and HCC78 cells are shown.  (B) Quantiﬁcation of angiogenesis.  The 
tumors treated with EGCG exhibited a signiﬁcant decrease in tumor vessels in all cell lines.  Studentʼs t-test.  ＊p＜0.05.
EGCG (100µM) 
GAPDH
PC-9 H1975
(‒)
RPC-9 H2228
(+)
HIF-1α
(‒)(+) (+) (‒) (+) (‒) (‒) (+)
HCC78
Fig. 6　 Eﬀects of EGCG on HIF-1α.  Western blotting analysis showed that HIF-1α was suppressed in PC-9,  RPC-9,  H1975,  H2228 and 
HCC78 cells with EGCG treatment.
here were significantly inhibited by EGCG treatment.  
The overexpression or accumulation of HIF-1α protein 
was associated with oncogenic events by up-regulating 
vascular endothelial growth factor (VEGF) expression 
and promoting the tumor-associated angiogenesis,  
which is a mechanism for cancer cells to survive 
hypoxia in the tumor microenvironment [19-21].  
EGCG has been reported to suppress the activity of 
HIF-1α [22 , 23].  We also confirmed that HIF-1α was 
suppressed in all the cell lines used here.  Although sev-
eral mechanisms are already thought to contribute to 
the inhibition of angiogenesis by EGCG,  including 
those involving VEGFR,  MET,  and fibroblast growth 
factor [4],  suppression of HIF-1α may also have played 
a role in the anti-angiogenesis in our study.  In addition,  
a previous report using xenograft models showed that 
EGCG had antiproliferative effects on A549 lung cancer 
cells harboring KRAS mutation [24].  In that study,  the 
antiangiogenic potential of EGCG was partially respon-
sible for the growth suppression of tumors,  similarly to 
our experiments.  EGCG seems to be effective for KRAS 
mutant lung cancers in addition to EGFR,  ALK,  and 
ROS1 mutant lung cancers.
EGCG treatment has been shown to impose a block-
ade of G1-to-S transition,  leading to G0/G1 arrest,  in 
an epidermoid carcinoma cell line (A431) [25].  In bili-
ary tract cancer cell lines treated with EGCG,  a 
decrease in G2/M and an increase in G0/G1 were 
observed [26].  In the future,  it will be important to 
further analyze the cell cycle in lung cancer cells treated 
with EGCG,  since such analysis could provide a clue to 
the possibility of combination therapy with chemother-
apeutic agents including cisplatin [26].
The mechanisms by which EGCG inhibits EGFR 
have been reviewed previously [4 , 5].  EGCG can inhibit 
EGFR activation by interfering with the binding of EGF 
to EGFR; alter lipid organization in the plasma mem-
brane and inhibit EGF binding to EGFR; and induce 
internalization of EGFR into endosomes [4].  In addi-
tion,  the phosphorylation of Akt and Erk were also 
suppressed because their upstream molecules,  such as 
EGFR,  MET,  and IGFR,  were inhibited by EGCG [4].  
However,  the fact that the principal mechanisms of 
action of EGCG remain unknown constitutes a limita-
tion of this study.
Although Akt and Erk,  which are downstream sig-
nals from EGFR,  ALK and ROS1,  were suppressed by 
50 or 100 μM of EGCG,  these EGCG concentrations 
were quite high.  Dietary EGCG treatment increased the 
serum EGCG level in the xenograft in a dose-depen-
dent manner [27].  However,  the serum concentration 
of EGCG in mice was reported to be 2 orders of magni-
tude lower than the IC50 of 20-100 μM observed in in 
vitro experiments [4].  It remains unresolved whether 
the therapeutic efficacy of EGCG observed in vivo 
reflected the mechanisms obtained in in vitro,  although 
there have been several studies evaluating the effect of 
the differences in the effective concentrations between 
the in vitro and in vivo experiments [4 , 28-30].  
Moreover,  we have no data concerning the IC50 values 
of EGCG for non-malignant cells.  Because human 
cholangiocarcinoma cells were 25 times more sensitive 
to EGCG than human embryonic kidney 293 T cells 
[31],  we expect that EGCG might have a tumor-selec-
tive antiproliferative effect.
In summary,  we demonstrated that EGCG pos-
sessed inhibitory effects on the growth of all the cell 
lines we tested.  PC-9 cells with EGFR mutation,  RPC-9 
and H1975 cells with resistant T790M mutation,  and 
H2228 and HCC78 cells with fusion mutation were sim-
ilarly sensitive to EGCG in vitro and in vivo.  EGCG 
suppressed angiogenesis,  and this effect may have been 
attributable to the inhibition of HIF-1α.  Treatment with 
EGCG may be warranted for this intractable cancer.
Acknowledgments.　Support was received in the form of grants from 
the Ministry of Education,  Culture,  Sports,  Science,  and Technology of 
Japan (nos. 21590995 (N. Takigawa) and 23390221 (K. Kiura)).
References
 1. Yang CS and Wang ZY: Tea and cancer: A review.  J Natl Cancer 
Inst (1993) 58: 1038-1049.
 2. Spiridione G,  Susan B,  Nadia C,  Luigi S,  Roberto B and Adriana A:  
Tumor invasion: molecular shears blunted by green tea.  Nat Med 
(1999) 5: 1216.
 3. Yang CS,  Landau J M,  Huang MT and Newmark HL: Inhibition of 
carcinogenesis by dietary polyphenolic compounds.  Annu Rev Nutr 
(2001) 21: 381-406.
 4. Yang CS,  Wang X,  Lu G and Picinich SC: Cancer prevention by 
tea: animal studies,  molecular mechanisms and human relevance.  
Nat Rev Cancer (2009) 9: 429-439.
 5. Khan N,  Afaq F,  Saleem M,  Ahmad N and Mukhtar H: Targeting 
multiple signaling pathways by green tea polyphenol (-)-epigallo-
catechin-3-gallate.  Cancer Res (2006) 66: 2500-2505.
 6. Sharma SV,  Bell DW,  Settleman J and Haber DA: Epidermal 
growth factor receptor mutations in lung cancer.  Nat Rev Cancer 
(2007) 7: 169-181.
 7. Kwak EL,  Bang YJ,  Camidge DR,  Shaw AT,  Solomon B and 
Maki RG: Anaplastic lymphoma kinase inhibition in non-small-cell 
December 2017 Eﬀects of EGCG on an NSCLC Cell Line 511
lung cancer.  N Engl J Med (2010) 28: 1693-1703.
 8. Choi YL,  Takeuchi K,  Soda M,  Inamura K,  Togashi Y and Hatano 
S: Identiﬁcation of novel isoforms of the EML4-ALK transforming 
gene in non-small cell lung cancer.  Cancer Res (2008) 68: 4971-
4976.
 9. Bergethon K,  Shaw AT,  Ou SH,  Katayama R,  Lovly CM and 
McDonald NT: ROS1 rearrangements deﬁne a unique molecular 
class of lung cancers.  J Clin Oncol (2012) 30: 863-870.
10. Ogino A,  Kitao H,  Hirano S,  Uchida A,  Ishiai M,  Kozuki T,  
Takigawa N,  Takata M,  Kiura K and Tanimoto M: Emergence of 
epidermal growth factor receptor T790M mutation during chronic 
exposure to geﬁtinib in a non-small cell lung cancer cell line.  
Cancer Res (2007) 67: 7807-7814.
11. Mosmann T: Rapid colorimetric assay for cellular growth and sur-
vival: application to Proliferation and cytotoxicity assays.  J Immunol 
Methods (1983) 65: 55-63.
12. Sah JF,  Balasubramanian S,  Eckert RL and Rorke EA:  
Epigallocatechin-3-gallate inhibits epidermal growth factor receptor 
signaling pathway.  Evidence for direct inhibition of ERK1/2 and 
AKT kinases.  J Biol Chem (2004) 279: 12755-12762.
13. Milligan SA,  Burke P,  Coleman DT,  Bigelow RL,  Steﬀan JJ,  
Carroll JL,  Williams BJ and Cardelli JA: The green tea polyphenol 
EGCG potentiates the antiproliferative activity of c-met and epider-
mal growth factor receptor inhibitors in non-small cell lung cancer 
cells.  Clin Cancer Res (2009) 15: 4885-4894.
14. Mok TS,  Wu Y-L,  Ahn M-J,  Garassino MC,  Kim HR,  Ramalingam 
SS,  Shepherd FA,  He Y,  Akamatsu H,  Theelen WS,  Lee CK,  
Sebastian M,  Templeton A,  Mann H,  Marotti M,  Ghiorghiu S and 
Papadimitrakopoulou VA: AURA3 Investigators.  Osimertinib or 
platinum-pemetrexed in EGFR T790M-positive lung cancer.  N Engl 
J Med (2017) 376: 629-640.
15. Katayama R,  Khan TM,  Benes C,  Lifshits E,  Ebi H,  Rivera VM,  
Shakespeare WC,  Iafrate AJ,  Engelman JA and Shaw AT: Thera-
peutic strategies to overcome crizotinib resistance in non-small cell 
lung cancers harboring the fusion oncogene EML4-ALK.  Proc Natl 
Acad Sci (2011) 108: 7535-7540.
16. Shaw AT,  Ou SH,  Bang YJ,  Camidge DR,  Solomon BJ,  Salgia R,  
Riely GJ,  Varella-Garcia M,  Shapiro GI,  Costa DB,  Doebele RC,  
Le LP,  Zheng Z,  Tan W,  Stephenson P,  Shreeve SM,  Tye LM,  
Christensen JG,  Wilner KD,  Clark JW and Iafrate AJ: Crizotinib in 
ROS1-rearranged non-small-cell lung cancer.  N Engl J Med (2014) 
371: 1963-1971.
17. Shaw AT,  Kim DW,  Mehra R,  Tan DS,  Felip E,  Chow LQ,  
Camidge DR,  Vansteenkiste J,  Sharma S,  De Pas T,  Riely GJ,  
Solomon BJ,  Wolf J,  Thomas M,  Schuler M,  Liu G,  Santoro A,  
Lau YY,  Goldwasser M,  Boral AL and Engelman JA: Ceritinib in 
ALK-rearranged non-small-cell lung cancer.  N Engl J Med (2014) 
370: 1189-1197.
18. Hanahan D and Folkman J: Patterns and emerging mechanisms of 
the angiogenic switch during tumorigenesis.  Cell (1996) 86: 353-
364.
19. Lamy S,  Gingras D and Béliveau R: Green tea catechins inhibit 
vascularendothelial growth factor receptor phosphorylation.  Cancer 
Res (2002) 62: 381-385.
20. Rodriguez SK,  Guo W,  Liu L,  Band MA,  Paulson EK and Meydani 
M: Green tea catechin,  epigallocatechin-3-gallate,  inhibits vascu-
lar endothelial growth factor angiogenic signaling by disrupting the 
formation of a receptor complex.  Int J Cancer (2006) 118: 1635-
1644.
21. Semenza GL: Targeting HIF-1 for cancer therapy.  Nat Rev Cancer 
(2003) 3: 721-732.
22. Zhang Q,  Tang X,  Lu Q,  Zhang Z,  Rao J and Le AD: Green tea 
extract and (-)-epigallo-catechin-3-gallate inhibit hypoxia- and 
serum-induced HIF-1alpha protein accumulation and VEGF expres-
sion in human cervical carcinoma and hepatoma cells.  Mol Cancer 
Ther (2006) 5: 1227-1238.
23. Fassina G,  Vene R,  Morini M,  Minghelli S,  Benelli R and Noonan 
DM: Mechanisms of inhibition of tumor angiogenesis and vascular 
tumor growth by epigallocatechin-3-gallate.  Clin Cancer Res (2004) 
10: 4865-4873.
24. Sakamoto Y,  Terashita N,  Muraguchi T,  Fukusato T and Kubota S:  
Eﬀects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer 
tumor growth and angiogenesis.  Biosci Biotechnol Biochem (2013) 
77: 1799-1803.
25. Ahmad N,  Cheng P and Mukhtar H: Cell cycle dysregulation by 
green tea polyphenol epigallocatechin-3-gallate.  Biochem Biophys 
Res Commun (2000) 275: 328-334.
26. Mayr C,  Wagner A,  Neureiter D,  Pichler M,  Jakab M,  Illig R,  
Berr F and Kiesslich T: The green tea catechin epigallocatechin 
gallate induces cell cycle arrest and shows potential synergism 
with cisplatin in biliary tract cancer cells.  BMC Complement Altern 
Med (2015) 15: 194.
27. Naasani I,  Ohhashi F,  Ohhara T,  Feng WY,  Johnston J,  Chan K 
and Tsuruo T: Blocking telomerase by dietary polyphenols is a 
major mechanism for limiting the growth of human cancer cells in 
vitro and vivo.  Cancer Res (2003) 63: 824-830.
28. Lu Y,  Yao R,  Yan Y,  Wang Y,  Hara Y,  Lubet RA and You M: A 
gene expression signature that can predict green tea exposure and 
chemopreventive eﬃcacy of lung cancer in mice.  Cancer Res 
(2006) 66: 1956-1963.
29. Yamane T,  Takahashi T,  Kuwata K,  Oya K,  Inagake M and Kitao Y:  
Inhibition of N-methyl-Nʼ-nitro-N-nitrosoguanidine-induced carcino-
genesis by (-)-epigallocatechin gallate in the rat glandular stomach.  
Cancer Res (1995) 55: 2081-2084.
30. Leone M,  Zhai D,  Sareth S,  Kitada S,  Reed JC and Pellecchia M:  
Cancer prevention by tea polyphenols is linked to their direct inhi-
bition of antiapoptotic Bcl-2-family proteins. Cancer Res (2003) 63:  
8118-8121.
31. Kwak TW,  Park SB,  Kim HJ,  Jeong YI and Kang DH: Anticancer 
activities of epigallocatechin-3-gallate against cholangiocarcinoma 
cells.  Onco Targets Ther (2016) 10: 137-144.
512 Honda et al. Acta Med.  Okayama　Vol.  71,  No.  6
